Huntington Beach, California – June 4th, 2026 – Leonhardt Ventures LLC announced today that it has prepared a provisional patent application covering methods, systems, devices, and protocols for the bioelectric controlled expression of Oxidative Stress Responsive Serine Rich Protein 1 (OSER1), a recently identified longevity-associated protein that has emerged as a promising regulator of healthy aging.
The technology has been exclusively licensed to Lionheart Health for commercialization in applications focused on healthspan extension, healthy aging, regenerative medicine, cognitive health, cardiovascular health, musculoskeletal health, and longevity optimization.
The provisional patent application builds upon Leonhardt Ventures’ extensive intellectual property portfolio involving bioelectric controlled expression of regenerative and healthspan-associated proteins including Klotho, Sirtuins, GDF10, GDF11, BDNF, VEGF, eNOS, Sonic Hedgehog, and other longevity-related signaling pathways.
Recent scientific findings have identified OSER1 as a FOXO-regulated protein associated with improved resistance to oxidative stress, preservation of mitochondrial integrity, and lifespan extension across multiple species. Researchers have reported that increased OSER1 expression extended lifespan in silkworms, nematodes, and fruit flies, while reduced OSER1 expression shortened lifespan and impaired mitochondrial function. Human genetic studies have also associated OSER1 variants with exceptional longevity.
Leonhardt Ventures’ provisional patent application seeks to leverage targeted bioelectric signaling protocols to safely and non-invasively stimulate endogenous OSER1 expression as part of comprehensive healthspan optimization programs.
“OSER1 may represent another important node in the longevity network regulated by FOXO transcription factors,” said Howard J. Leonhardt, Founder and Executive Chairman of Leonhardt Ventures LLC and Lionheart Health, Inc. “Our goal is to investigate whether precision bioelectric signaling can activate the body’s own production of OSER1 in a manner that complements our ongoing work with Klotho, Sirtuins, BDNF, GDF10, VEGF, and other healthspan-associated proteins.”
Potential future applications under investigation include:
• Healthy aging and longevity optimization
• Mitochondrial health support
• Oxidative stress reduction
• Cognitive performance and brain health
• Cardiovascular wellness
• Musculoskeletal performance and recovery
• Frailty prevention programs
• Personalized longevity medicine programs
• Bioelectric-enhanced regenerative medicine therapies
The company plans to evaluate OSER1 expression within future Lionheart Health clinical programs and healthspan studies.
About Leonhardt Ventures LLC
Founded in 1982, Leonhardt Ventures LLC develops bioelectric, regenerative medicine, cardiovascular, orthopedic, dental, and longevity technologies. The company has generated more than 800 patent claims across multiple therapeutic areas.
About Lionheart Health, Inc.
Lionheart Health is a healthspan longevity and regenerative medicine company focused on bioelectric controlled protein expression, enhanced biologics, longevity programs, and personalized health optimization technologies.
Forward-Looking Statements
This release contains forward-looking statements regarding research, development, and commercialization plans. Actual results may differ materially from those anticipated. Bioelectric OSER1 expression technologies remain investigational and are not currently approved by the U.S. Food and Drug Administration for the treatment, prevention, or cure of any disease.
Scientific References Supporting OSER1 as a Longevity Target
Primary Scientific Publication
- Song J, Li Z, Zhou L, Chen X, Sew WQG, Herranz H, Ye Z, Olsen JV, Li Y, Nygaard M, Christensen K, Tong X, Bohr VA, Rasmussen LJ, Dai F. “FOXO-regulated OSER1 reduces oxidative stress and extends lifespan in multiple species.” Nature Communications. 2024;15:7144. DOI: 10.1038/s41467-024-51542-z.
Key Findings Reported
- OSER1 identified as an evolutionarily conserved FOXO-regulated longevity protein.
- Increased OSER1 expression extended lifespan in silkworms, nematodes, and fruit flies.
- Reduced OSER1 expression shortened lifespan and impaired mitochondrial function.
- OSER1 improved resistance to oxidative stress, starvation, and heat shock.
- Human genetic variants in OSER1 were associated with longevity.
- OSER1 appears linked to oxidative stress response, cellular senescence, mitochondrial integrity, and healthy aging pathways.
Researchers Credit Acknowledgment
The OSER1 longevity discovery was led primarily by researchers including:
- Lene Juel Rasmussen
- Zhiquan Li
- Jiangbo Song
- Fangyin Dai
- Vilhelm A. Bohr
- Kaare Christensen